Additional practice changes, including BRCA1 and BRCA2 mutation testing by gynecologic oncologists and reflex tumor testing by the Department of Pathology, may also be evaluated in future years to determine their impact on detecting BRCA1/2 positivity (i.e., rates). The gene discussed is BRCA1; the disease is neoplasm.